Akros SCHK HK-Korea Cosmetics Index

Samsung Biologics expects to publish the formal PolyPeptide tender-offer prospectus by the end of August 2026.

Yuhan Corp is due to file its H1 2026 interim report by August 14, 2026, creating the next formal earnings and Lazcluze-royalty disclosure catalyst.

Samchundang Pharm’s statutory deadline to file its 2026 first-half report is August 14, 2026.

Peptron is due to file its 2026 first-half report by August 14, 2026, providing the next scheduled company financial and operating update before September 7.

Independent financial calendars list SK Biopharmaceuticals’ Q2 2026 earnings release for August 11, 2026.

Hanmi Pharm is scheduled to report 2Q26 results on 2026-07-28, with analysts estimating sharply higher revenue and operating profit chiefly from Lilly's USD 75 million sonefpeglutide upfront payment.

HLB said Elevar completed the FDA late-cycle meeting for lirafugratinib in previously treated FGFR2 fusion/rearrangement-positive cholangiocarcinoma without new approval-affecting review issues.

Celltrion submitted updated global Phase 3 trial applications for CT-P13 SC (Zymfentra) in rheumatoid arthritis to the FDA, EMA and South Korea's MFDS.

Celltrion submitted a European marketing-authorization application for CT-P55, its secukinumab biosimilar referencing Cosentyx, across the reference product's EU indications.

Hanmi announced research presented at ISMB 2026 showing that its HARP-pSAR AI platform was used to derive the muscle-preserving obesity candidate HM17321, which remains in U.S. Phase 1.

Chairman Yoon Dae-in’s concert party disclosed an extension of pledges over 337,610 Samchundang Pharm shares, while its aggregate ownership remained 37.61%.

The Korea Exchange extended Samchundang Pharm's short-selling trading ban through 2026-07-23 after its initial short-selling-overheat designation.

Samsung Biologics filed its preliminary Q2 2026 results on DART, reporting revenue of KRW 1.3209 trillion and operating profit of KRW 586.4 billion, up 30.2% and 22.9% year over year, respectively.

The Ministry of Food and Drug Safety imposed manufacturing suspensions beginning July 21 on Samchundang Pharm’s nasal-spray dosage form and Lefurozine Syrup for manufacturing-control and recall-procedure failures.

Hana Securities forecast SK Biopharmaceuticals’ Q2 2026 revenue of KRW 238.5 billion and operating profit of KRW 88.5 billion, respectively 2.0% and 4.7% above consensus.